Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trinity BiotechTRIB -1.52%30 3-Year EBITDA Growth Rate is 39.00% as of Dec. 2025, which is 650% above its 10-year median of 5.20. GuruFocus rates TRIB with a GF Score™ of 30/100 and a GF Value™ of $23.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Trinity Biotech ranks better than 83.04% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 39.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Trinity Biotech was 179.10% per year. The lowest was -49.50% per year. And the median was 5.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Trinity Biotech 3-Year EBITDA Growth Rate Related Terms
TRIB vs STME, VVOS, AIDX: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Trinity Biotech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 39.00% mean?
Trinity Biotech (TRIB) has a 3-Year EBITDA Growth Rate of 39.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Trinity Biotech and its competitors. This is 650% above median its historical median of 5.20. According to the industry distribution chart, Trinity Biotech ranks #117 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 17%.
Is Trinity Biotech's 3-Year EBITDA Growth Rate too high?
Trinity Biotech's current 3-Year EBITDA Growth Rate of 39.00% is 650% above median its 10-year median of 5.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Trinity Biotech's value of 39.00% is 375.6% above this industry median. Based on the distribution chart, Trinity Biotech ranks #117 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Trinity Biotech has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's 3-Year EBITDA Growth Rate compare to STME and VVOS?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #117 out of 690 companies for 3-Year EBITDA Growth Rate. This places Trinity Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Trinity Biotech's value of 39.00% is 375.6% above this benchmark. While the company's 10-year median is 5.20 vs. the industry median of 8.20, Trinity Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trinity Biotech's current 3-Year EBITDA Growth Rate of 39.00% is 375.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current 3-Year EBITDA Growth Rate is 39.00%, which is 650% above median its own 10-year median of 5.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $23.15, compared to a current price of $11.67 — trading 49.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 39.00%, which is 650% above median its 10-year median of 5.20 and 375.6% above the Medical Devices & Instruments industry median of 8.20. Trinity Biotech's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current 3-Year EBITDA Growth Rate is 39.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $11.67 is trading 49.6% below its estimated GF Value™ of $23.15.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
3-Year EBITDA Growth Rate: 39.00% (650% above median its 10-year median of 5.20)
GF Value™: $23.15 vs. price of $11.67 (49.6% below fair value)
Industry Position: 375.6% above the Medical Devices & Instruments median (#117 of 690)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
30GF Score
Get the complete analysis for TRIB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
